Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686842 · ClinicalTrials.gov registry record · Phase 1
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00686842 is a Phase 1 study that was terminated before completion, run by AIDS Malignancy Consortium. The registered enrollment target is 17 participants.
The verdict
NCT00686842, a Phase 1 study, was terminated before completion, sponsored by AIDS Malignancy Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- GENETIC polymerase chain reaction
- OTHER immunohistochemistry staining method
- DRUG VEGF inhibitor PTC299
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686842
The ClinicalTrials.gov registry entry for NCT00686842 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00686842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686842 about?
NCT00686842 is a clinical study titled "PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma". RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.
What is the current status of trial NCT00686842?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00686842?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), polymerase chain reaction (GENETIC), immunohistochemistry staining method (OTHER), VEGF inhibitor PTC299 (DRUG).
Who is sponsoring clinical trial NCT00686842?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.